MedTrace Logo

Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, Ghana

NCT02078024 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 375

Last updated 2019-04-26

No results posted yet for this study

Summary

We will examine whether a combination of Ivermectim (IVM) plus Albendazole (ALB) compared to IVM alone given annually, which is the current standard for mass drug administration (MDA), is more effective in sterilizing adult worms. We will also address whether IVM plus ALB given twice per year is superior to IVM given once per year or twice per year.

Conditions

  • Onchocerciasis

Interventions

DRUG

IVM plus ALB

DRUG

IVM

Sponsors & Collaborators

  • University Hospitals Cleveland Medical Center

    lead OTHER

Principal Investigators

  • Christopher L King, MD, PhD · Case Western Reserve University

  • James W Kazura, MD · Case Western Reserve University

  • Nicholas O Opoku, MBChB, MSc · Municipal Hospital, Hohoe, Ghana

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2018-06-30
Completion
2018-06-25

Countries

  • Ghana

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02078024 on ClinicalTrials.gov